menu
    • menu
    [{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Syngene International Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syngene International Limited \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Syngene International Limited \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Vaxart","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syngene International Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syngene International Limited \/ Vaxart","highestDevelopmentStatusID":"8","companyTruncated":"Syngene International Limited \/ Vaxart"}]

    Find Clinical Drug Pipeline Developments & Deals by Syngene International Limited

    Menu

    Syngene International Limited

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syngene International Limited

                            India arrow
                            Luxepack
                            Not Confirmed

                            Syngene International Limited

                            India arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VXA-CoV2-1.1-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Vaxart

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine

                            Details : VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.

                            Brand Name : VXA-CoV2-1.1-S

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : VXA-CoV2-1.1-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Vaxart

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syngene International Limited

                            India arrow
                            Luxepack
                            Not Confirmed

                            Syngene International Limited

                            India arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030

                            Details : The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutica...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth